FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1561-1568 June 13, 1996 Number 24 Next

Abstract PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Yang, C.-H. J. PubMed Citation

ABSTRACT

Background In patients with hepatocellular carcinoma (hepatoma), the rate of recurrent and second primary hepatomas is high despite surgical resection and percutaneous ethanol-injection therapy. We developed an acyclic retinoid, polyprenoic acid, that inhibits hepatocarcinogenesis in the laboratory and induces differentiation and apoptosis in cell lines derived from human hepatoma. In a randomized, controlled study, we tested whether the compound reduced the incidence of recurrent and second primary hepatomas after curative treatment.

Methods We prospectively studied 89 patients who were free of disease after surgical resection of a primary hepatoma or the percutaneous injection of ethanol. We randomly assigned the patients to receive either polyprenoic acid (600 mg daily) or placebo for 12 months. We studied the remnant liver by ultrasonography every three months after randomization. The primary end point of the study was the appearance of a histologically confirmed recurrent or new hepatoma.

Results Treatment with polyprenoic acid significantly reduced the incidence of recurrent or new hepatomas. After a median follow-up of 38 months, 12 patients in the polyprenoic acid group (27 percent) had recurrent or new hepatomas as compared with 22 patients in the placebo group (49 percent, P = 0.04). The most striking difference was in the groups that had second primary hepatomas — 7 in the group receiving polyprenoic acid as compared with 20 in the placebo group (P = 0.04 by the log-rank test). Cox proportional-hazards analysis demonstrated that as an independent factor, polyprenoic acid reduced the occurrence of second primary hepatomas (adjusted relative risk, 0.31; 95 percent confidence interval, 0.12 to 0.78).

Conclusions Oral polyprenoic acid prevents second primary hepatomas after surgical resection of the original tumor or the percutaneous injection of ethanol.

In attempts to develop novel synthetic compounds for cancer chemoprevention, we found a 20-carbon polyprenoic acid (3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) (Figure 1) that binds to the cellular retinoic acid–binding protein and has relatively low toxicity.¹⁰ This agent inhibits chemically induced hepatocarcinogenesis in rats and spontaneous hepatocellular carcinomas (hepatomas) in mice^11,12,13 and suppresses cell growth and the production of alpha-fetoprotein in human-hepatoma–derived cell lines.¹⁴ Its action is mediated in part through the retinoic acid receptor and the retinoid X receptor.¹⁵ Hence, this compound can be called an open-chain, or acyclic, retinoid.¹⁶

View larger version (2K): [in this window] [in a new window]   Figure 1. Chemical Structure of Polyprenoic Acid (3,7,11,15-Tetramethyl-2,4,6,10,14-hexadecapentaenoic Acid).

 
Phase 1 trials of polyprenoic acid were conducted in 35 healthy subjects at doses of 25, 75, 150, 300, and 600 mg per day. One subject who received 600 mg per day had hyperlipidemia, whereas the others tolerated that dose with no adverse effects. In 12 patients with liver cirrhosis who were given 300 or 600 mg per day, 1 patient receiving the 600-mg dose reported oral dryness, whereas the others had no physical or laboratory abnormalities (Aoyama M, Eisal Co., Ltd.: personal communication).

Since the rates of tumor recurrence and of the occurrence of second primary tumors determine the long-term prognosis in patients with primary hepatoma,^{17,18,19,20,21,22,23} we conducted a randomized, controlled study to test whether polyprenoic acid prevents recurrences and second primary hepatomas after curative surgical resection or the percutaneous injection of ethanol into the initial hepatoma.

Methods

Patients

The study involved six clinical centers where patients underwent curative surgical resection of a hepatoma or received a percutaneous injection of ethanol into at least one histologically confirmed hepatoma. The patients selected for the study were considered to be free of further hepatoma by ultrasonography and plain and contrast-enhanced computed tomography (CT) of the entire remnant liver and by blood tests, including determinations of alpha-fetoprotein. Intraoperative ultrasonography was performed in every patient who underwent surgical resection. The selection of patients began in September 1990, and follow-up data on all the patients were updated in February 1996.

The evaluation of each patient before entry into the study included a history taking, physical examination, and appropriate laboratory assessment. To be eligible, the patients had to have good performance status and be under 75 years of age. Each patient's tumor was graded on the basis of the clinical criteria defined by the Liver Cancer Study Group of Japan.²⁴ We excluded patients with a serum total bilirubin level higher than 5.0 mg per deciliter (84 µmol per liter) and those with any severe cardiac, renal, or hematologic disorder that might be worsened by the agent.

The study protocol was approved by the review board for research on human subjects at each institution. Written informed consent, including an agreement not to take vitamin A supplements during the study, was obtained from each patient.

Study Design

At the beginning of the study, we assumed that the incidence of recurrent and second primary hepatomas would be approximately 40 to 50 percent over a two-year period^{17,18,19,20,21,22,23} and that the active treatment would reduce the incidence to about half that found in our previous studies.^11,12,13 Using these assumptions and a table proposed by Gehan,²⁵ we calculated that the study sample would require 40 patients in each group, with an alpha error of 5 percent and a beta error of 20 percent.

We reviewed data on 111 potentially eligible patients, 89 of whom were found to be eligible and willing to participate and to provide informed consent. Of the 22 patients who were not randomized, 12 were unwilling to participate in the study, 7 moved to hospitals not involved in the study, 2 did not have serum bilirubin levels in the required range, and 1 was found to have been treated with fluorouracil immediately after surgery.

We randomly assigned the 89 patients to receive active treatment or placebo (peanut oil), with blocking according to study center. The study design called for 14 patients to be randomized at each center, and the actual numbers ranged from 11 to 23 (median, 14). The active treatment was 600 mg of polyprenoic acid daily (two 150-mg capsules taken twice daily) for 12 months. This dose was chosen to correspond to the level of intake that had shown a benefit in laboratory studies and because its safety had been demonstrated in a phase 1 trial. We provided the placebo or polyprenoic acid (Eisai) in soft, opaque gelatin capsules packaged in calendar packs. We recovered the packs every month to confirm patients' compliance with the prescribed regimen. The treatment assignments were not revealed to the patients, their doctors, or the study investigators until the end of the trial.

The study treatment began no later than eight weeks after the surgery or ethanol injection. The protocol called for an ultrasonographic examination every three months and CT every six months during the treatment and follow-up periods. At each visit, CT included plain scanning and helical scanning with rapid intravenous infusion of contrast material. The resulting images were considered satisfactory for the study purposes if all the segments of the remnant liver could be seen. At each visit, we asked the patient about symptoms, performed a physical examination, and noted the patient's general condition. We also obtained a specimen of venous blood for laboratory tests, including the measurement of alpha-fetoprotein levels. An aliquot of plasma was stored at -80°C for the measurement of plasma levels of the study drug by high-performance liquid chromatography after the end of the trial.

End Points

The primary end point was the occurrence of new hepatomas. At each visit for ultrasonography and CT examination, the size and location of all lesions that may have represented treatment failures were recorded; biopsies of all were performed within one week for histologic confirmation of the diagnosis of hepatoma.

Any hepatoma that developed six or more months after the diagnosis of the first tumor was termed a "metachronous," or late, treatment failure; one that developed earlier was termed a "synchronous," or early, treatment failure.²⁶ In analyzing the cancer-preventive effect of polyprenoic acid, we defined any early treatment failure or distant metastasis as representing the progression (or recurrence) of the disease caused by the first tumor. Late treatment failures were considered to involve second primary hepatomas when they met certain strict conditions, as follows. A second primary hepatoma had to be in a liver segment different from the initial hepatoma in patients who received percutaneous injections of ethanol. In patients who had undergone surgery, a second primary hepatoma had to be separated by more than 2 cm of normal liver tissue from the margin of resection. In both patients who received percutaneous injections of ethanol and those who underwent surgery, the histologic grade of cancer²⁴ of the second primary hepatoma had to at least equal that of the initial hepatoma. Hepatomas that developed in the metachronous period but did not fulfill these criteria were considered to indicate progression of disease. Our criteria for second primary hepatomas incorporated the characteristics of multicentric hepatomas but excluded the features of intrahepatic metastasis from a single clone of hepatoma.^27,28,29 These standards agree well with the criteria for multicentric hepatoma recommended by the Liver Cancer Study Group of Japan.^17,24,30

The secondary end point of the study was survival. Absolute and disease-free survival were both measured in each patient, beginning with the date of randomization.

Statistical Analysis

Our principal hypothesis concerned the effect of treatment with polyprenoic acid on the proportion of patients with at least one new hepatoma during the study period. We estimated survival curves according to the method of Kaplan and Meier and assessed the differences between the treatment groups by the log-rank test. All P values were two-tailed.

We used the Cox proportional-hazards model to produce adjusted estimates and 95 percent confidence intervals for the relative risk of the development of new hepatomas associated with selected variables at study entry, including the study assignment; the patient's age and sex; the cause of the underlying liver disease; number of earlier hepatomas, their size, and the method of treatment; the clinical stage; and the plasma levels of alanine aminotransferase, alpha-fetoprotein, and retinol.

Results

Patterns of Treatment Failure

Of the 89 patients who enrolled in the study, 44 were randomly assigned to the polyprenoic acid group and 45 to the placebo group. There were no statistically significant differences between the groups with regard to the factors considered to influence treatment failure: age, sex, cause and activity of underlying liver disease, number and size of primary hepatomas, and type of primary treatment (Table 1).

View this table: [in this window] [in a new window]   Table 1. Demographic and Clinical Characteristics of the Patients at Entry into the Study.

 
The median follow-up for all patients was 38 months from the date of randomization. During this period, at least one histologically confirmed hepatoma developed in 34 patients (38 percent) (Table 2). New hepatomas were identified first by ultrasonography in all 34 patients; in 16, they were identified by CT at the same time. The mean (±SD) serum alpha-fetoprotein concentrations in the 34 patients who had second hepatomas did not differ significantly from those in the 55 patients who did not have such hepatomas at the end of the follow-up period (45±32 vs. 35±22 ng per milliliter).

View this table: [in this window] [in a new window]   Table 2. Incidence of Treatment Failure.

 
The proportion of patients who had second hepatomas was significantly lower in the polyprenoic acid group than in the placebo group (27 percent vs. 49 percent, P = 0.04) (Table 2). In particular, polyprenoic acid reduced the rate of second primary hepatomas (16 percent, vs. 44 percent with placebo; P = 0.004), whereas the incidence of disease recurrence did not differ between the two groups (Table 2). All the patients in whom second hepatomas developed more than six months after the initial hepatoma met the criteria for having a metachronous tumor. No patient had distant metastasis as an end point.

The characteristics of the 27 patients with second primary hepatomas are shown in Table 3. In all 27, the histologic grade²⁴ of both the initial and the second hepatoma was well-differentiated hepatocellular carcinoma (grade I to II of the classification system of Edmondson and Steiner³¹). The characteristics of treatment failure, including the length of time from the first treatment to the second occurrence and the segment, histologic grade, number, and size of the second hepatomas, did not differ significantly between the patients who received percutaneous injections of ethanol and those who underwent surgical resection.

View this table: [in this window] [in a new window]   Table 3. Characteristics of the Patients with Second Primary Hepatomas.

 
Toxicity and Compliance

Each of the 89 patients took at least one capsule containing polyprenoic acid or placebo during the study and were included in the analyses of toxicity. One patient given polyprenoic acid had severe headache on the first day of therapy, and the drug was discontinued. In the placebo group, one patient had a severe skin eruption and one had moderate nausea, necessitating discontinuation of therapy in each. No typical toxic effects of retinoids, such as dry skin, cheilitis, or conjunctivitis, were observed in either group, nor were any abnormal laboratory data possibly related to treatment reported in either group. Mean serum triglyceride levels were 9.6 mg per deciliter (0.11 mmol per liter) at entry and 11.7 mg per deciliter (0.13 mmol per liter) at one year in the active-treatment group and 9.5 and 10.7 mg per deciliter (0.11 and 0.12 mmol per liter), respectively, in the placebo group; these differences were not significant.

Five of the 44 patients in the active-treatment group (11 percent) did not complete the course of treatment: 1 because of toxic effects and 4 because of noncompliance. In the remaining 39 patients, the mean plasma levels of polyprenoic acid reached 44.9±13.9 ng per milliliter at one year. Six of the 45 patients in the placebo group discontinued therapy because of toxic effects (2 patients) or noncompliance (4).

Survival

Survival curves were estimated for absolute survival, disease-free survival until either the primary tumor progressed or a second primary tumor appeared, and survival until a second primary hepatoma appeared. As compared with placebo, polyprenoic acid reduced the incidence of treatment failure in all three categories, but only the change in the incidence of second primary hepatomas was significant (P = 0.04). Kaplan–Meier estimates of the proportion of patients free of second primary hepatomas over time are shown in Figure 2.

View larger version (2K): [in this window] [in a new window]   Figure 2. Kaplan–Meier Estimates of the Proportion of Patients without Second Primary Hepatomas in the Two Study Groups. The treatment period lasted for 12 months, beginning with month 0. P = 0.04 for the comparison between groups by the log-rank test. Tick marks indicate patients who withdrew or were excluded from the study.

 
When polyprenoic acid was compared with placebo by the proportional-hazards model, the estimated relative risk of a second primary hepatoma was 0.31 (95 percent confidence interval, 0.12 to 0.78); the relative risk of any type of treatment failure (either a recurrence or the appearance of a second primary hepatoma) was 0.49 (95 percent confidence interval, 0.25 to 1.1); the relative risk of death was 0.50 (95 percent confidence interval, 0.19 to 1.1). The median duration of absolute survival had not yet been reached in either group as of this writing.

Discussion

We investigated the effect of a derivative of polyprenoic acid (an acyclic retinoid) on the incidence of new hepatomas after curative treatment of the initial hepatoma. Retinoids are considered chemopreventive but not chemotherapeutic, because they mainly inhibit the promotion of carcinogenesis, but not the later phases of conversion and progression.^1,2,3,4 Accordingly, we hypothesized that polyprenoic acid would have a greater effect on second primary hepatomas than on recurrent tumors. In fact, it significantly reduced the incidence of second primary hepatomas (P = 0.004 for the direct comparison with placebo after a median follow-up of 38 months), but not the failure rates associated with the three types of disease progression. These results may explain why polyprenoic acid did not significantly affect disease-free survival, which included recurrences. Taken together, our data show that polyprenoic acid can prevent second primary tumors in patients who are clinically free of disease after their primary hepatomas are treated. As for absolute survival, the overall survival rate remains over 80 percent at this writing, and we estimate that at least another 48 months will be required for us to detect a statistically significant difference between groups, assuming that the curves continue to have slopes similar to the current ones.

The patients' clinical characteristics, including age, sex, and the cause of the underlying chronic liver disease, were similar to those reported in the general survey of Japanese patients with hepatoma.^17,30 The incidence of treatment failure of any type two years after the end of the primary treatment in the placebo group (49 percent) was also in the range previously reported.^{17,18,19,20,21,22,23} Hence, the patients in this study were representative patients with hepatoma. Risk factors that may be related to the occurrence of new tumors after the treatment of small hepatomas — including the size and number of the hepatomas treated, the functional reserve of the liver, and the degree of inflammation of liver parenchyma (as measured by the serum alanine aminotransferase activity)^{17,18,19,20,21,22,23,30,32,33,34,35,36,37,38,39,40,41,42} — did not differ between groups. The method of treating the initial hepatoma, whether it was surgical resection or percutaneous injection of ethanol, was also studied in a stratified analysis between the groups. After adjustment for these characteristics, multivariate analysis revealed that the upper bound of the 95 percent confidence interval of the relative risk of a second primary hepatoma was less than 1 in the group treated with polyprenoic acid, giving further evidence of the efficacy of the compound.

Hepatoma associated with chronic viral diseases of the liver is a major health problem in countries such as Japan, where rates of infection with the hepatitis B and C viruses in the general population are as high as 1 to 2 percent.^43,44 The annual death rate from hepatoma in Japan exceeds 25,000, and such disease is the third leading cause of death due to cancer in Japanese men.⁴⁵ Advances in medical imaging permit the early diagnosis and treatment of hepatoma,^46,47 but in the most recent reports,^17,18,30 the five-year survival rate barely reached 40 percent. The low rate of survival after any treatment is due to the high incidence of recurrent tumors and second primary tumors. The incidence of second hepatomas is approximately 25 percent one year after radical surgical resection and about 50 percent after two years.^{17,19,20,21,30} The percutaneous injection of ethanol can produce survival rates at three to five years that equal or exceed those obtained by surgical resection.^17,22,23 Surgical resection decreases liver mass and may lead to liver failure, whereas the percutaneous injection of ethanol minimally damages the surrounding noncancerous liver tissue. Hence, such injections are preferred to surgery in patients with hepatoma and chronic viral liver disease,^17,22,23 who have a high incidence of recurrent hepatoma and may require repeated treatment. However, the rates of second hepatomas in the remnant liver after surgical resection or after the percutaneous injection of ethanol do not differ,^{17,18,19,20,21,22,23} as we found in this study.

The high incidence of second primary hepatoma in our study is in accord with the concept of field cancerization,⁴⁸ which postulates that cancer arises from a field that is exposed to a continuous carcinogenic insult. The tissue that constitutes the field forms multiple precancerous foci and undergoes multicentric carcinogenesis.⁴⁹ In chronic viral liver disease, a typical example of this concept,⁵⁰ second primary hepatomas frequently develop despite treatment. Chemoprevention of hepatocarcinogenesis may therefore improve the prognosis. Our study is noteworthy in that all new hepatomas were identified first by ultrasonography rather than CT or the determination of serum alpha-fetoprotein levels, a fact that confirms the superior diagnostic ability of ultrasonography for small hepatomas.^46,47

We found polyprenoic acid to be safe. Plasma drug levels were in the range that was reached in the phase 1 trial and that showed effects in vivo^11,12,13 and in vitro.^14,15 Only 1 of the 44 patients who took the drug had headache. Other toxic effects of retinoids, such as skin eruptions, musculoskeletal disorders, decreased visual acuity, anemia, and hyperlipidemia,⁵¹ did not appear.

Hepatocarcinogenesis is closely related to the impaired metabolism of retinoid. The retinoid content of hepatoma tissue starts to decline early in carcinogenesis.^11,52,53 Cellular levels of retinol-binding protein decrease and cellular levels of retinoic acid–binding protein increase in both precancerous and cancerous hepatic conditions.^11,53,54 A cohort study demonstrated an inverse dose–response relation between the serum retinol level before diagnosis and the development of hepatoma.⁵⁵ Thus, many attempts have been made in the laboratory to test the efficacy of retinoids on hepatocarcinogenesis.^{3,11,12,13,56,57,58,59,60}

The mechanism of action of polyprenoic acid is unknown. In human-hepatoma–derived cell lines, this compound brought a return of the characteristics of differentiated hepatocytes, such as the synthesis and secretion of albumin, through a signal that began with the binding of the compound to the retinoid X receptor.^14,15 Polyprenoic acid also induced differentiation in promyelocytic leukemia cells.⁶¹ It caused apoptosis in hepatoma cell lines by blocking the autocrine and paracrine loops of transforming growth factor .⁶² Deletion of an L3-positive hepatoma clone^63,64,65 has also been suggested (unpublished data).

Further research is under way to develop potent and safe analogues of polyprenoic acid.⁶⁶ Such compounds may prevent primary hepatomas, since short-term use of polyprenoic acid in low doses inhibited the spontaneous development of mouse hepatomas for more than two years.⁶⁷

Supported in part by grants from the Princess Takamatsu Cancer Research Fund; the Ministry of Education, Science, and Culture; and the Ministry of Health and Welfare of Japan.

We are indebted to the late Yoshikazu Suzuki, to whom this article is dedicated; to Masahide Aoyama, Masahiro Bando, and Isao Yamatsu, of the Department of Clinical Development, Eisai Co., Ltd., for their strong support; to Ms. Rie Nishiwaki, Gifu University School of Medicine, for her excellent analysis of plasma drug levels by high-performance liquid chromatography; and to Dr. Yoshihiro Shidoji, Gifu University School of Medicine, for invaluable discussion and suggestions in preparing this manuscript.

^* Additional members of the Hepatoma Prevention Study Group are listed in the Appendix.

Source Information

From the First Department of Internal Medicine (Y.M., H.M., S.A., M.O.) and the Departments of Pathology (T.T.) and Pharmacology (K.T.), Gifu University School of Medicine, Gifu; the Institute of Gastroenterology, Tokyo Women's Medical College, Tokyo (A.S., K.T.T.); the Gastrointestinal Disease Center, Gifu Municipal Hospital, Gifu (E.T.); Gihoku Hospital, Takatomi (M.N.); Gifu Red Cross Hospital, Gifu (T.N.); and Murakami Memorial Hospital, Asahi University, Gifu (T.K.) — all in Japan.

Address reprint requests to Dr. Muto at the First Department of Internal Medicine, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu 500, Japan.

References

1. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979;38:2528-2534. [Medline]
2. Sporn MB. Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res 1991;51:6215-6218. [Free Full Text]
3. Moon RC, Mehta RG, Rao KVN. Retinoids and cancer in experimental animals. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry, and medicine. 2nd ed. New York: Raven Press, 1994:573-95.
4. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 1990;50:2-9. [Free Full Text]
5. Hong WK, Itri LM. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry, and medicine. 2nd ed. New York: Raven Press, 1994:597-630.
6. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1492. [Free Full Text]
7. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-1035. [Free Full Text]
8. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 1994;331:141-147. [Free Full Text]
9. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801. [Abstract]
10. Muto Y, Moriwaki H, Omori M. In vitro binding affinity of novel synthetic polyprenoids (polyprenoic acids) to cellular retinoid-binding proteins. Jpn J Cancer Res [Gann] 1981;72:974-7.
11. Muto Y, Moriwaki H. Antitumor activities of vitamin A and its derivatives. J Natl Cancer Inst 1984;73:1389-1393.
12. Moriwaki H, Muto Y, Ninomiya M, Kawai K, Suzuki Y, Seto T. Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3'-methyl-N,N-dimethyl-4-aminoazobenzene. J Gastroenterol 1988;23:546-552. 
13. Muto Y, Kawai K, Moriwaki H. Antitumor activity of a novel synthetic polyprenoic acid (E-5166) on `spontaneous' hepatic tumors of C3H/HeNCrj mice. In: Saurat JH, ed. Retinoids: new trends in research and therapy. Basel, Switzerland: Karger, 1985:293-7.
14. Fukutomi Y, Omori M, Muto Y, Ninomiya M, Okuno M, Moriwaki H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn J Cancer Res [Gann] 1990;81:1281-5.
15. Yamada Y, Shidoji Y, Fukutomi Y, et al. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994;10:151-158. [Medline]
16. Muto Y, Moriwaki H. Acyclic retinoids and cancer chemoprevention. Pure Appl Chem 1991;63:157-160.
17. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan: report 11. Acta Hepatol Jpn 1995;36:208-18.
18. Kita K, Ebara M, Sugiura N, Ohto M. Percutaneous ethanol injection (PEI) for small hepatocellular carcinoma -- study on its therapeutic effect and prognosis based on long-term observation. Nippon Shokakibyo Gakkai Zasshi 1994;91:1946-1955. [Medline]
19. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analysis. Hepatology 1991;14:802-805. [Medline]
20. Yamasaki S, Hasegawa H, Takayama T, et al. Clinicopathological features of recurrent primary liver cancer in Japan. In: Okuda K, ed. Primary liver cancer in Japan. Tokyo, Japan: Springer-Verlag, 1992:345-51.
21. Ikeda K, Saitoh S, Tsubota A, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993;71:19-25. [CrossRef][Medline]
22. Ohto M, Ebara M, Watanabe Y, et al. Percutaneous ethanol injection therapy (PEI) for small hepatocellular carcinoma: evaluation of its utility on the basis of tumor-images and survival after therapy. Jpn J Med Imaging 1988;7:25-33.
23. Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: study of 95 patients. J Gastroenterol Hepatol 1990;5:616-626. [Medline]
24. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd ed. Tokyo, Japan: Kanehara, 1992:20-6. (In Japanese.)
25. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:203-223. [Free Full Text]
26. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer 1932;16:1358-414.
27. Sakamoto M, Hirohashi S, Tsuda H, Shimosato Y, Makuuchi M, Hosoda Y. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 1989;13:1064-1067. [Medline]
28. Esumi M, Aritaka T, Arii M, et al. Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res 1986;46:5764-5771. 
29. Tsuda H, Hirohashi S, Shimosato Y, Terada M, Hasegawa H. Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 1988;95:1664-1666. [Medline]
30. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994;74:2772-2780. [CrossRef][Medline]
31. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503. [CrossRef][Medline]
32. Yamanaka M, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas: a univariate and multivariate analysis. Cancer 1990;65:1104-1110. [CrossRef][Medline]
33. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991;214:114-117. [Medline]
34. Nagao T, Inoue S, Yoshimi F, et al. Prospective recurrence of hepatocellular carcinoma. Ann Surg 1990;211:28-33. [Medline]
35. Jwo SC, Chiu JH, Chau GY, Loong CC, Lui WY. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology 1992;16:1367-1371. [Medline]
36. Sugioka T, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993;113:612-618. [Medline]
37. Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993;105:488-494. [Medline]
38. Matsumata T, Kanematsu T, Takenaka K,Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology 1989;9:457-460. [Medline]
39. Arii S, Tanaka J, Yamazoe Y, et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992;69:913-919. [CrossRef][Medline]
40. Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma: result of 229 consecutive patients during 11 years. Ann Surg 1993;217:375-384. [Medline]
41. Chiu JH, Wu LH, Kao HL, et al. Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma? Hepatology 1993;18:96-102. [Erratum, Hepatology 1993;18:1292.] [Medline]
42. Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-775. [CrossRef][Medline]
43. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Lancet 1991;338:1040-1041. [CrossRef][Medline]
44. Kiyosawa K, Sodeyama T, Tanaka E, et al. Intrafamilial transmission of hepatitis C virus in Japan. J Med Virol 1991;33:114-116. [Medline]
45. Health and Welfare Statistics Association. Annual report of disease-related deaths in Japan. J Health Welfare Stat 1994;41:Suppl 9:47-60.
46. Shinagawa T, Ohto M, Kimura K, et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography: a study in 51 patients. Gastroenterology 1984;86:495-4950 2. [Medline]
47. Ebara M, Ohto M, Kondo F. Strategy for early diagnosis of hepatocellular carcinoma (HCC). Ann Acad Med Singapore 1989;18:83-89. [Medline]
48. Slaughter DP, Southwick HW, Smejkal W. "Field cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-968. [CrossRef][Medline]
49. Chen PJ, Chen DS, Lai MY, et al. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989;96:527-529. [Medline]
50. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-675. [Medline]
51. Armstrong RB, Ashenfelter KO, Eckhoff C, Levin AA, Shapiro SS. General and reproductive toxicology of retinoids. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids: biology, chemistry, and medicine. 2nd ed. New York: Raven Press, 1994:545-72.
52. Muto Y, Omori M, Sugawara K. Demonstration of a novel cellular retinol-binding protein, F-type, in hepatocellular carcinoma. Jpn J Cancer Res [Gann] 1979;70:215-22.
53. Moriwaki H, Muto Y, Ninomiya M, Shimizu M, Takahashi Y. Time course of changes in cellular retinoid-binding proteins in liver hyperplastic nodules and hepatocellular carcinoma experimentally induced in rats. Acta Hepatol Jpn 1982;23:523-9.
54. Muto Y, Omori M. A novel cellular retinoid-binding protein, F-type, in hepatocellular carcinoma. Ann N Y Acad Sci 1981;359:91-103. [Medline]
55. Yu M-W, Hsieh H-H, Pan W-H, Yang C-S, Chen C-J. Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 1995;55:1301-1305. [Free Full Text]
56. Daoud AH, Griffin AC. Effect of retinoic acid, butylated hydroxytoluene, selenium, and sorbic acid on azo-dye hepatocarcinogenesis. Cancer Lett 1980;9:299-304. [CrossRef][Medline]
57. Mack DO, Reed VL, Smith LD. Retinyl acetate inhibition of 3'-methyl-4-dimethyl-aminoazobenzene induced hepatic neoplasia. Int J Biochem 1990;22:359-365. [Medline]
58. Curphey TJ, Kuhlman ET, Roebuck BD, Longnecker DS. Inhibition of pancreatic and liver carcinogenesis in rats by retinoid- and selenium-supplemented diets. Pancreas 1988;3:36-40. [Medline]
59. Baba M, Iishi H, Yamamoto R, Tatsuta M. Inhibition by retinoic acid of hepatocarcinogenesis induced by N-nitrosomorpholine and of expression of myc oncogene protein in Sprague-Dawley rats. Int J Cancer 1991;49:467-470. [Medline]
60. Maiorana A, Gullino PM. Effect of retinyl acetate on the incidence of mammary carcinomas and hepatomas in mice. J Natl Cancer Inst 1980;64:655-663.
61. Tsurumi H, Tojo A, Takahashi T, et al. Differentiation induction of human promyelocytic leukemia cells by acyclic retinoid (polyprenoic acid). Int J Hematol 1993;59:9-15. [Medline]
62. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Muto Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995;207:382-388. [CrossRef][Medline]
63. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993;328:1802-1806. [Free Full Text]
64. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-5423. [Free Full Text]
65. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995;22:802-807. [CrossRef][Medline]
66. Araki H, Shidoji M, Yamada Y, Moriwaki H, Muto Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem Biophys Res Commun 1995;209:66-72. [CrossRef][Medline]
67. Hatakeyama H, Shidoji Y, Omori M, et al. Retardation effect of acyclic retinoid on spontaneous hepatocarcinogenesis without changes in incidence of c-Ha-ras mutations in C3H/HeNCrj mice. Center Detect Prev (in press).

In addition to the study authors, the investigators in the Hepatoma Prevention Study Group included T. Yamatsu, First Department of Internal Medicine, Gifu University School of Medicine; Y. Nishigaki, Gastrointestinal Disease Center, Gifu Municipal Hospital; H. Okuno, T. Kasai, and K. Takagi, Gihoku Hospital; Y. Ito, Gifu Red Cross Hospital; and H. Koda, Murakami Memorial Hospital, Asahi University.

Abstract PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Yang, C.-H. J. PubMed Citation

Related Letters:

Polyprenoic Acid in Hepatocellular Carcinoma
Yang C.-H. J., Cheng A.-L., Decensi A., Costa A., Muto Y., Moriwaki H., Okuno M.
Extract | Full Text  
N Engl J Med 1996; 335:1460-1462, Nov 7, 1996. Correspondence

This article has been cited by other articles:

• Hoshida, Y., Nijman, S. M.B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., Watanabe, G., Gabriel, S., Friedman, S. L., Kumada, H., Llovet, J. M., Golub, T. R. (2009). Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Res. 69: 7385-7392 [Abstract] [Full Text]  
• NAKAYAMA, Y., INOUE, Y., MINAGAWA, N., ONITSUKA, K., NAGATA, J., SHIBAO, K., HIRATA, K., SAKO, T., NAGATA, N., YAMAGUCHI, K. (2009). Chemopreventive Effect of 4-[3,5-Bis(trimethylsilyl) benzamido] Benzoic Acid (TAC-101) on MNU-induced Colon Carcinogenesis in a Rat Model. Anticancer Res 29: 2059-2065 [Abstract] [Full Text]  
• Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., Reich, M., Chan, J. A., Glickman, J. N., Ikeda, K., Hashimoto, M., Watanabe, G., Daidone, M. G., Roayaie, S., Schwartz, M., Thung, S., Salvesen, H. B., Gabriel, S., Mazzaferro, V., Bruix, J., Friedman, S. L., Kumada, H., Llovet, J. M., Golub, T. R. (2008). Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. NEJM 359: 1995-2004 [Abstract] [Full Text]  
• Shimizu, M., Fukutomi, Y., Ninomiya, M., Nagura, K., Kato, T., Araki, H., Suganuma, M., Fujiki, H., Moriwaki, H. (2008). Green Tea Extracts for the Prevention of Metachronous Colorectal Adenomas: A Pilot Study. Cancer Epidemiol. Biomarkers Prev. 17: 3020-3025 [Abstract] [Full Text]  
• Tatebe, H., Shimizu, M., Shirakami, Y., Tsurumi, H., Moriwaki, H. (2008). Synergistic Growth Inhibition by 9-cis-Retinoic Acid Plus Trastuzumab in Human Hepatocellular Carcinoma Cells. Clin. Cancer Res. 14: 2806-2812 [Abstract] [Full Text]  
• Boucher, E., Bouguen, G., Garin, E., Guillygomarch, A., Boudjema, K., Raoul, J.-L. (2008). Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up. JNM 49: 362-366 [Abstract] [Full Text]  
• Yamazaki, K., Shimizu, M., Okuno, M., Matsushima-Nishiwaki, R., Kanemura, N., Araki, H., Tsurumi, H., Kojima, S., Weinstein, I B., Moriwaki, H. (2007). Synergistic effects of RXR{alpha} and PPAR{gamma} ligands to inhibit growth in human colon cancer cells phosphorylated RXR{alpha} is a critical target for colon cancer management. Gut 56: 1557-1563 [Abstract] [Full Text]  
• Qu, C.-X., Kamangar, F., Fan, J.-H., Yu, B., Sun, X.-D., Taylor, P. R., Chen, B. E., Abnet, C. C., Qiao, Y.-L., Mark, S. D., Dawsey, S. M. (2007). Chemoprevention of Primary Liver Cancer: A Randomized, Double-Blind Trial in Linxian, China. JNCI J Natl Cancer Inst 99: 1240-1247 [Abstract] [Full Text]  
• Kada, N., Suzuki, T., Aizawa, K., Matsumura, T., Ishibashi, N., Suzuki, N., Takeda, N., Munemasa, Y., Sawaki, D., Ishikawa, T., Nagai, R. (2007). Acyclic Retinoid Inhibits Neointima Formation Through Retinoic Acid Receptor Beta-Induced Apoptosis. Arterioscler. Thromb. Vasc. Bio. 27: 1535-1541 [Abstract] [Full Text]  
• Zhu, A. X. (2006). Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?. The Oncologist 11: 790-800 [Abstract] [Full Text]  
• Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., Papadimitrakopoulou, V. A., Lotan, R., Aggarwal, B. B., Bresalier, R. S., Kim, J., Arun, B., Lu, K. H., Thomas, M. E., Rhodes, H. E., Brewer, M. A., Follen, M., Shin, D. M., Parnes, H. L., Siegfried, J. M., Evans, A. A., Blot, W. J., Chow, W.-H., Blount, P. L., Maley, C. C., Wang, K. K., Lam, S., Lee, J. J., Dubinett, S. M., Engstrom, P. F., Meyskens, F. L. Jr., O'Shaughnessy, J., Hawk, E. T., Levin, B., Nelson, W. G., Hong, W. K., for the AACR Task Force on Cancer Prevention, (2006). Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward. Clin. Cancer Res. 12: 3661-3697 [Abstract] [Full Text]  
• Freemantle, S. J., Dragnev, K. H., Dmitrovsky, E. (2006). The retinoic Acid paradox in cancer chemoprevention.. JNCI J Natl Cancer Inst 98: 426-427 [Full Text]  
• Yuan, J.-M., Gao, Y.-T., Ong, C.-N., Ross, R. K., Yu, M. C. (2006). Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma.. JNCI J Natl Cancer Inst 98: 482-490 [Abstract] [Full Text]  
• Okudaira, T., Tomita, M., Uchihara, J.-N., Matsuda, T., Ishikawa, C., Kawakami, H., Masuda, M., Tanaka, Y., Ohshiro, K., Takasu, N., Mori, N. (2006). NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-{kappa}B signal pathway.. Molecular Cancer Therapeutics 5: 704-712 [Abstract] [Full Text]  
• Thomas, M. B., Abbruzzese, J. L. (2005). Opportunities for Targeted Therapies in Hepatocellular Carcinoma. JCO 23: 8093-8108 [Abstract] [Full Text]  
• de Almeida Vasconcelos Fonseca, E. M., Chagas, C. E. A., Mazzantini, R. P., Heidor, R., Ong, T. P., Moreno, F. S. (2005). All-trans and 9-cis retinoic acids, retinol and {beta}-carotene chemopreventive activities during the initial phases of hepatocarcinogenesis involve distinct actions on glutathione S-transferase positive preneoplastic lesions remodeling and DNA damage. Carcinogenesis 26: 1940-1946 [Abstract] [Full Text]  
• Ueno, S., Aoki, D., Kubo, F., Hiwatashi, K., Matsushita, K., Oyama, T., Maruyama, I., Aikou, T. (2005). Roxithromycin Inhibits Constitutive Activation of Nuclear Factor {kappa}B by Diminishing Oxidative Stress in a Rat Model of Hepatocellular Carcinoma. Clin. Cancer Res. 11: 5645-5650 [Abstract] [Full Text]  
• Tanabe, K. K., Blaszkowsky, L. S., Chung, R. T., Blake, M. A., Lauwers, G. Y. (2005). Case 23-2005 - A 57-Year-Old Man with a Mass in the Liver. NEJM 353: 401-410 [Full Text]  
• de Moura Espindola, R., Mazzantini, R. P., Ong, T. P., de Conti, A., Heidor, R., Moreno, F. S. (2005). Geranylgeraniol and {beta}-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-{kappa}B activation. Carcinogenesis 26: 1091-1099 [Abstract] [Full Text]  
• Thomas, M. B., Zhu, A. X. (2005). Hepatocellular Carcinoma: The Need for Progress. JCO 23: 2892-2899 [Full Text]  
• Hayashi, M., Tamura, T., Kuroda, J., Ohnota, H., Shibata, N., Akahane, M., Kashida, Y., Mitsumori, K. (2005). Different Inhibitory Effects in the Early and Late Phase of Treatment with KAT-681, a Liver-Selective Thyromimetic, on Rat Hepatocarcinogenesis Induced by 2-Acetylaminofluorene and Partial Hepatectomy after Diethylnitrosamine Initiation. Toxicol Sci 84: 22-28 [Abstract] [Full Text]  
• Shimizu, M., Suzui, M., Deguchi, A., Lim, J. T. E., Xiao, D., Hayes, J. H., Papadopoulos, K. P., Weinstein, I. B. (2004). Synergistic Effects of Acyclic Retinoid and OSI-461 on Growth Inhibition and Gene Expression in Human Hepatoma Cells. Clin. Cancer Res. 10: 6710-6721 [Abstract] [Full Text]  
• Shidoji, Y., Ogawa, H. (2004). Natural occurrence of cancer-preventive geranylgeranoic acid in medicinal herbs. J. Lipid Res. 45: 1092-1103 [Abstract] [Full Text]  
• Kagawa, M., Sano, T., Ishibashi, N., Hashimoto, M., Okuno, M., Moriwaki, H., Suzuki, R., Kohno, H., Tanaka, T. (2004). An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-{alpha} expression and cell proliferation. Carcinogenesis 25: 979-985 [Abstract] [Full Text]  
• Dragnev, K. H., Pitha-Rowe, I., Ma, Y., Petty, W. J., Sekula, D., Murphy, B., Rendi, M., Suh, N., Desai, N. B., Sporn, M. B., Freemantle, S. J., Dmitrovsky, E. (2004). Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy. Clin. Cancer Res. 10: 2570-2577 [Abstract] [Full Text]  
• Suzui, M., Shimizu, M., Masuda, M., Lim, J. T. E., Yoshimi, N., Weinstein, I. B. (2004). Acyclic retinoid activates retinoic acid receptor {beta} and induces transcriptional activation of p21CIP1 in HepG2 human hepatoma cells. Molecular Cancer Therapeutics 3: 309-316 [Abstract] [Full Text]  
• Kuang, M., Peng, B. G., Lu, M. D., Liang, L. J., Huang, J. F., He, Q., Hua, Y. P., Totsuka, S., Liu, S. Q., Leong, K. W., Ohno, T. (2004). Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical Recurrence of Hepatocellular Carcinoma. Clin. Cancer Res. 10: 1574-1579 [Abstract] [Full Text]  
• Shimizu, M., Suzui, M., Deguchi, A., Lim, J. T. E., Weinstein, I. B. (2004). Effects of Acyclic Retinoid on Growth, Cell Cycle Control, Epidermal Growth Factor Receptor Signaling, and Gene Expression in Human Squamous Cell Carcinoma Cells. Clin. Cancer Res. 10: 1130-1140 [Abstract] [Full Text]  
• Wang, Y., Fang, M. Z., Liao, J., Yang, G.-Y., Nie, Y., Song, Y., So, C., Xu, X., Wang, L.-D., Yang, C. S. (2003). Hypermethylation-Associated Inactivation of Retinoic Acid Receptor {beta} in Human Esophageal Squamous Cell Carcinoma. Clin. Cancer Res. 9: 5257-5263 [Abstract] [Full Text]  
• Kakizoe, T. (2003). Chemoprevention of Cancer - Focusing on Clinical Trials. Jpn J Clin Oncol 33: 421-442 [Abstract] [Full Text]  
• Matsushima-Nishiwaki, R., Okuno, M., Takano, Y., Kojima, S., Friedman, S. L., Moriwaki, H. (2003). Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24: 1353-1359 [Abstract] [Full Text]  
• Yamamoto, S., Tomita, Y., Nakamori, S., Hoshida, Y., Nagano, H., Dono, K., Umeshita, K., Sakon, M., Monden, M., Aozasa, K. (2003). Elevated Expression of Valosin-Containing Protein (p97) in Hepatocellular Carcinoma Is Correlated With Increased Incidence of Tumor Recurrence. JCO 21: 447-452 [Abstract] [Full Text]  
• Wang, X.-D. (2003). Retinoids and Alcohol-Related Carcinogenesis. J. Nutr. 133: 287S-290 [Abstract] [Full Text]  
• Dragnev, K. H., Stover, D., Dmitrovsky, E. (2003). Lung Cancer Prevention: The Guidelines. Chest 123 : 60S-71S [Abstract] [Full Text]  
• Johnson, P J (2002). Hepatocellular carcinoma: is current therapy really altering outcome?. Gut 51: 459-462 [Abstract] [Full Text]  
• Suzui, M., Masuda, M., Lim, J. T. E., Albanese, C., Pestell, R. G., Weinstein, I. B. (2002). Growth Inhibition of Human Hepatoma Cells by Acyclic Retinoid Is Associated with Induction of p21CIP1 and Inhibition of Expression of Cyclin D1. Cancer Res. 62: 3997-4006 [Abstract] [Full Text]  
• Oyama, K., Shiota, G., Ito, H., Murawaki, Y., Kawasaki, H. (2002). Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis 23: 885-892 [Abstract] [Full Text]  
• Rodriguez-Burford, C., Barnes, M. N., Oelschlager, D. K., Myers, R. B., Talley, L. I., Partridge, E. E., Grizzle, W. E. (2002). Effects of Nonsteroidal Anti-Inflammatory Agents (NSAIDs) on Ovarian Carcinoma Cell Lines: Preclinical Evaluation of NSAIDs as Chemopreventive Agents. Clin. Cancer Res. 8: 202-209 [Abstract] [Full Text]  
• Matsushima-Nishiwaki, R., Okuno, M., Adachi, S., Sano, T., Akita, K., Moriwaki, H., Friedman, S. L., Kojima, S. (2001). Phosphorylation of Retinoid X Receptor {alpha} at Serine 260 Impairs Its Metabolism and Function in Human Hepatocellular Carcinoma. Cancer Res. 61: 7675-7682 [Abstract] [Full Text]  
• Okada, S. (2001). Cancer Chemoprevention as Adjuvant Therapy for Hepatocellular Carcinoma. Jpn J Clin Oncol 31: 357-358 [Full Text]  
• Okuno, M., Sano, T., Matsushima-Nishiwaki, R., Adachi, S., Akita, K., Okano, Y., Kojima, S., Moriwaki, H. (2001). Apoptosis Induction by Acyclic Retinoid: a Molecular Basis of 'Clonal Deletion' Therapy for Hepatocellular Carcinoma. Jpn J Clin Oncol 31: 359-362 [Abstract] [Full Text]  
• Chung, J., Liu, C., Smith, D. E., Seitz, H. K., Russell, R. M., Wang, X.-D. (2001). Restoration of retinoic acid concentration supresses ethanol-enhanced c-Jun expression and hepatocyte proliferation in rat liver. Carcinogenesis 22: 1213-1219 [Abstract] [Full Text]  
• Maruyama, S., Nagasue, N., Dhar, D. K., Yamanoi, A., El-Assal, O. N., Satoh, K., Okita, K. (2001). Preventive Effect of FK143, a 5{{alpha}}-Reductase Inhibitor, on Chemical Hepatocarcinogenesis in Rats. Clin. Cancer Res. 7: 2096-2104 [Abstract] [Full Text]  
• Poon, R. T.-P., Ng, I. O.-L., Fan, S.-T., Lai, E. C.-S., Lo, C.-M., Liu, C.-L., Wong, J. (2001). Clinicopathologic Features of Long-Term Survivors and Disease-Free Survivors After Resection of Hepatocellular Carcinoma: A Study of a Prospective Cohort. JCO 19: 3037-3044 [Abstract] [Full Text]  
• Bilimoria, M. M., Lauwers, G. Y., Doherty, D. A., Nagorney, D. M., Belghiti, J., Do, K.-A., Regimbeau, J.-M., Ellis, L. M., Curley, S. A., Ikai, I., Yamaoka, Y., Vauthey, J.-N. (2001). Underlying Liver Disease, Not Tumor Factors, Predicts Long-term Survival After Resection of Hepatocellular Carcinoma. Arch Surg 136: 528-535 [Abstract] [Full Text]  
• Lippman, S. M., Lee, J. J., Karp, D. D., Vokes, E. E., Benner, S. E., Goodman, G. E., Khuri, F. R., Marks, R., Winn, R. J., Fry, W., Graziano, S. L., Gandara, D. R., Okawara, G., Woodhouse, C. L., Williams, B., Perez, C., Kim, H. W., Lotan, R., Roth, J. A., Hong, W. K. (2001). Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer. JNCI J Natl Cancer Inst 93: 605-618 [Abstract] [Full Text]  
• Okabe, H., Satoh, S., Kato, T., Kitahara, O., Yanagawa, R., Yamaoka, Y., Tsunoda, T., Furukawa, Y., Nakamura, Y. (2001). Genome-wide Analysis of Gene Expression in Human Hepatocellular Carcinomas Using cDNA Microarray: Identification of Genes Involved in Viral Carcinogenesis and Tumor Progression. Cancer Res. 61: 2129-2137 [Abstract] [Full Text]  
• Dragnev, K. H., Rigas, J. R., Dmitrovsky, E. (2000). The Retinoids and Cancer Prevention Mechanisms. The Oncologist 5: 361-368 [Abstract] [Full Text]  
• Wu, K., Kim, H.-T., Rodriquez, J. L., Munoz-Medellin, D., Mohsin, S. K., Hilsenbeck, S. G., Lamph, W. W., Gottardis, M. M., Shirley, M. A., Kuhn, J. G., Green, J. E., Brown, P. H. (2000). 9-cis-Retinoic Acid Suppresses Mammary Tumorigenesis in C3(1)-Simian Virus 40 T Antigen-transgenic Mice. Clin. Cancer Res. 6: 3696-3704 [Abstract] [Full Text]  
• Lippman, S. M., Lotan, R. (2000). Advances in the Development of Retinoids as Chemopreventive Agents. J. Nutr. 130: 479-479 [Abstract] [Full Text]  
• (1999). Prevention of Cancer in the Next Millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res. 59: 4743-4758 [Full Text]  
• Torzilli, G., Makuuchi, M., Inoue, K., Takayama, T., Sakamoto, Y., Sugawara, Y., Kubota, K., Zucchi, A. (1999). No-Mortality Liver Resection for Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients: Is There a Way? A Prospective Analysis of Our Approach. Arch Surg 134: 984-992 [Abstract] [Full Text]  
• Leachman, S. A., Insogna, K. L., Katz, L., Ellison, A., Milstone, L. M. (1999). Bone Densities in Patients Receiving Isotretinoin for Cystic Acne. Arch Dermatol 135: 961-965 [Abstract] [Full Text]  
• Muto, Y., Moriwaki, H., Saito, A. (1999). Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma. NEJM 340: 1046-1047 [Full Text]  
• Boyle, J. O., Langenfeld, J., Lonardo, F., Sekula, D., Reczek, P., Rusch, V., Dawson, M. I., Dmitrovsky, E. (1999). Cyclin D1 Proteolysis: a Retinoid Chemoprevention Signal in Normal, Immortalized, and Transformed Human Bronchial Epithelial Cells. JNCI J Natl Cancer Inst 91: 373-379 [Abstract] [Full Text]  
• Hong, W. K., Sporn, M. B. (1997). Recent Advances in Chemoprevention of Cancer. Science 278: 1073-1077 [Abstract] [Full Text]  
• Langenfeld, J., Kiyokawa, H., Sekula, D., Boyle, J., Dmitrovsky, E. (1997). Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism. Proc. Natl. Acad. Sci. USA 94: 12070-12074 [Abstract] [Full Text]  
• Wren, S. M., Coburn, M. M., Tan, M., Daniels, J. R., Yassa, N., Carpenter, C. L., Stain, S. C. (1997). Is Cryosurgical Ablation Appropriate for Treating Hepatocellular Cancer?. Arch Surg 132: 599-604 [Abstract]  
• Yang, C.-H. J., Cheng, A.-L., Decensi, A., Costa, A., Muto, Y., Moriwaki, H., Okuno, M. (1996). Polyprenoic Acid in Hepatocellular Carcinoma. NEJM 335: 1460-1462 [Full Text]  
• Shafritz, D. A. (1996). Synthetic Retinoids for the Secondary Prevention of Hepatocellular Carcinoma. NEJM 334: 1600-1601 [Full Text]